Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institute of Oncology Ljubljana
Breast cancer patients undergoing breast-conserving surgery are treated with adjuvant radiotherapy using either standard fractionation or hypofractionation combined with a simultaneous integrated boost (SIB) to the tumor bed. This prospective study includes systematic collection and grading of acute and late radiation-related toxicity outcomes in order to evaluate the safety of the implemented protocol and to assess whether toxicity rates are comparable to those reported in published clinical studies. The results will support optimization and quality assurance of the radiotherapy technique in routine clinical practice.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients with histologically confirmed breast cancer
Status post breast-conserving surgery (lumpectomy)
Planned adjuvant whole-breast radiotherapy with simultaneous integrated boost (SIB) to the tumor bed
Age ≥ 18 years
Ability to provide informed consent
You may not be if
Prior radiotherapy to the breast or thoracic region
Mastectomy (no breast-conserving surgery)
Pregnancy or breastfeeding
Inability to complete planned radiotherapy or follow-up assessments
Clareo Health | Toxicity Outcomes of Simultaneous Integrated Boost in Adjuvant Breast Radiotherapy Acronym
